A Post-marketing Observational Database Study Monitoring the Safety of CecolinⓇ
NCT06824896 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1322084
Last updated 2025-02-13
Summary
This study was a retrospective-prospective real-world study to assess the safety among females receiving the 2vHPV vaccine (CecolinⓇ).
Conditions
- Autoimmune Diseases
- Adverse Pregnancy Outcomes
Sponsors & Collaborators
-
Xiamen University
collaborator OTHER -
Xiamen Health and Medical Big Data Center
collaborator UNKNOWN -
Xiamen Innovax Biotech Co., Ltd
lead INDUSTRY
Eligibility
- Min Age
- 9 Years
- Max Age
- 45 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-06-06
- Primary Completion
- 2024-06-30
- Completion
- 2024-06-30
Countries
- China
Study Locations
More Related Trials
-
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
NCT01290393 ·Status: TERMINATED
-
Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity
NCT06137352 ·Status: NOT_YET_RECRUITING
-
Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls
NCT06243666 ·Status: ACTIVE_NOT_RECRUITING
-
Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study
NCT01418937 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
NCT01249365 ·Status: COMPLETED ·Phase: PHASE3
-
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
NCT05056402 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
NCT01462357 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls
NCT04508309 ·Status: COMPLETED ·Phase: PHASE3
-
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
NCT00456807 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
NCT03935204 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
NCT00652938 ·Status: COMPLETED ·Phase: PHASE3
-
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
NCT05371353 ·Status: RECRUITING
-
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
NCT01190189 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
NCT00250276 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions
NCT06658405 ·Status: RECRUITING ·Phase: PHASE2
-
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
NCT00996125 ·Status: COMPLETED ·Phase: PHASE3
-
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
NCT00359619 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects
NCT03929172 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects
NCT00426361 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
NCT04537156 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
NCT00637195 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
NCT00811798 ·Status: COMPLETED ·Phase: PHASE3
-
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
NCT01953822 ·Status: COMPLETED
-
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
NCT00546078 ·Status: COMPLETED ·Phase: PHASE2
-
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
NCT00365443 ·Status: WITHDRAWN ·Phase: PHASE2